

Megan Neary

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4770226/publications.pdf>

Version: 2024-02-01

18
papers

479
citations

1170033

9
h-index

939365

18
g-index

27
all docs

27
docs citations

27
times ranked

973
citing authors

#	ARTICLE	IF	CITATIONS
1	Linear and branched polymer prodrugs of the water-soluble nucleoside reverse-transcriptase inhibitor emtricitabine as structural materials for long-acting implants. <i>Journal of Materials Chemistry B</i> , 2022, 10, 4395-4404.	2.9	3
2	Dose prediction for repurposing nitazoxanide in SARS-CoV-2 treatment or chemoprophylaxis. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 2078-2088.	1.1	46
3	Scalable nanoprecipitation of niclosamide and <i>in vivo</i> demonstration of long-acting delivery after intramuscular injection. <i>Nanoscale</i> , 2021, 13, 6410-6416.	2.8	11
4	Prioritization of Anti-SARS-CoV-2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 775-790.	2.3	118
5	Do genetic variations in proximal tubule transporters influence tenofovir-induced renal dysfunction? An exploratory study in a Ghanaian population. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 1267-1271.	1.3	4
6	Genetic influence of ABCG2, UGT1A1 and NR1I2 on dolutegravir plasma pharmacokinetics. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 1259-1266.	1.3	6
7	Pharmacokinetics of HIV therapies in pregnant patients: an update. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2020, 16, 449-461.	1.5	2
8	Pharmacokinetics of Efavirenz 400 mg Once Daily Coadministered With Isoniazid and Rifampicin in Human Immunodeficiency Virus-Infected Individuals. <i>Clinical Infectious Diseases</i> , 2019, 68, 446-452.	2.9	21
9	Meta-analysis of the effect of CYP2B6, CYP2A6, UGT2B7 and CAR polymorphisms on efavirenz plasma concentrations. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 3281-3290.	1.3	15
10	Effect of patient genetics on etonogestrel pharmacokinetics when combined with efavirenz or nevirapine ART. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 3003-3010.	1.3	13
11	Rifampicin effect on intracellular and plasma pharmacokinetics of tenofovir alafenamide. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 1670-1678.	1.3	42
12	A Lower Dose of Efavirenz Can Be Coadministered With Rifampicin and Isoniazid in Tuberculosis Patients. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz035.	0.4	5
13	Impact of pharmacogenetics and pregnancy on tenofovir and emtricitabine pharmacokinetics. <i>Pharmacogenomics</i> , 2019, 20, 217-223.	0.6	4
14	Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics of Efavirenz 400 mg Once Daily During Pregnancy and Post-Partum. <i>Clinical Infectious Diseases</i> , 2018, 67, 785-790.	2.9	25
15	The Effect of Gene Variants on Levonorgestrel Pharmacokinetics When Combined With Antiretroviral Therapy Containing Efavirenz or Nevirapine. <i>Clinical Pharmacology and Therapeutics</i> , 2017, 102, 529-536.	2.3	28
16	Pharmacogenetic considerations for HIV treatment in different ethnicities: an update. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017, 13, 1169-1181.	1.5	8
17	Pregnancy affects nevirapine pharmacokinetics. <i>Pharmacogenetics and Genomics</i> , 2016, 26, 381-389.	0.7	10
18	The role of drug transporters in the kidney: lessons from tenofovir. <i>Frontiers in Pharmacology</i> , 2014, 5, 248.	1.6	62